Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 42   

Articles published

ARNA 4.52
price chart
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
Insider Sales: Arena Pharmaceuticals, VIVUS Inc, Amarin Corporation
There has been an interesting trend among three noteworthy pharmaceutical companies like Arena Pharmaceuticals, Inc.
Vivus Looks Into European Approval As Company Pins Hopes On Qsymia  Seeking Alpha
Will pill-popping beat obesity?  Stuff.co.nz
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
The Potential Market For Arena's Belviq
... because the product the company we invest in has real potential. There is a substantial difference between potential market and the real market for any given product.
What Slims Down Fastest After Diet Drugs Are Approved by he FDA? Two Stocks ...  YCharts
Short Interest in Biotech Firms on the Rise
Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date.
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
In prior articles I've talked about Synergy Pharmaceuticals (NASDAQ:SGYP) as a fantastic under-the-radar biotech stock for 2012.
Shattered Trust | Watchdog Update Hartland wipes manufacturer Triad files for ...
Triad Group Inc. and sister company H&P Industries Inc. are seeking protection from creditors under Chapter 11 - a provision that enables financially troubled firms to negotiate down their debts and continue in business.
Can Designers And Developers Save Health Care?
Participants who lost 7% of their body weight through dietary changes and increased physical activity dramatically diminished their chances of developing diabetes, soundly defeating the pharmaceuticals. So how was this life-changing intervention ...
Earnings Preview: Orexigen Therapeutics
On June 27, 2012, Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the U.S. Food and Drug Administration has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight ...